<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Thyroid physiology and screening in preterm infants
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Thyroid physiology and screening in preterm infants
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Thyroid physiology and screening in preterm infants
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kara Connelly, MD, MCR
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stephen LaFranchi, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David S Cooper, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mitchell E Geffner, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alison G Hoppin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 07, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Congenital hypothyroidism occurs in approximately 1 in 2000 to 1 in 4000 newborns worldwide, with considerable regional and racial/ethnic variation. It is one of the most common treatable causes of intellectual disability. However, most newborn babies with this disorder have few or no clinical manifestations of thyroid hormone deficiency. In addition, the majority of cases are sporadic, so it is not possible to predict which infants are likely to be affected. For these reasons, newborn screening programs were developed to detect and treat this condition as early as possible, by measuring either thyroxine (T4) and/or thyrotropin (thyroid-stimulating hormone [TSH]) in heel stick blood specimens. These screening efforts were initiated in the mid-1970s and have been largely successful, although severely affected infants may still have a slightly reduced intelligence quotient (IQ) and other neurologic deficits despite prompt diagnosis and initiation of therapy. (See
         <a class="medical medical_review" href="/z/d/html/5836.html" rel="external">
          "Clinical features and detection of congenital hypothyroidism"
         </a>
         .)
        </p>
        <p>
         Interpretation of screening tests in a preterm neonate requires an understanding of thyroid physiology in the fetus throughout gestation. This topic will review normal thyroid physiology in the fetus and following birth in preterm and term infants.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          NORMAL THYROID PHYSIOLOGY IN THE FETUS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The bilobed thyroid shape is evident by seven weeks of gestation, and thyroid follicles containing colloid are seen histologically by 10 weeks. With respect to thyroid function, thyroglobulin synthesis can be detected at four weeks, iodine trapping at 8 to 10 weeks, and thyroxine (T4) and, to a lesser extent, triiodothyronine (T3) synthesis and secretion at 12 weeks. Hypothalamic neurons contain thyrotropin-releasing hormone (TRH) at six to eight weeks, the pituitary-portal vascular system begins to develop at 8 to 10 weeks, and thyrotropin (thyroid-stimulating hormone [TSH]) secretion can be detected at 12 weeks. Maturation of the hypothalamic-pituitary-thyroid axis occurs during the second half of gestation, but completely normal feedback relationships are not mature until term gestation or early postnatal life. (See
         <a class="medical medical_review" href="/z/d/html/7837.html" rel="external">
          "Thyroid hormone synthesis and physiology"
         </a>
         .)
        </p>
        <p>
         The pattern of changes during gestation is as follows (
         <a class="graphic graphic_figure graphicRef68673" href="/z/d/graphic/68673.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid1">
          1,2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         During the first trimester, T4 in the circulation is of maternal origin, as the fetal thyroid does not produce significant amounts of T4 until the second half of pregnancy [
         <a href="#rid3">
          3
         </a>
         ]. Thereafter, the rise in serum T4 concentrations is a result of both an increase in hepatic production of thyroxine-binding globulin (TBG) and, to a lesser degree, an increase in fetal thyroidal T4 production stimulated by TSH secretion. Fetal serum T4 concentrations rise from a mean of approximately 2 mcg/dL (26 nmol/L) at 12 weeks to 10 mcg/dL (128 nmol/L) at term [
         <a href="#rid1">
          1,2
         </a>
         ]. Fetal serum free T4 concentrations also increase progressively, from a mean value of approximately 0.1 ng/dL (1.3 pmol/L) at 12 weeks to 2 ng/dL (25.7 pmol/L) at term.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fetal serum total and free T3 concentrations increase much less because of placental inner ring deiodination of T4 to reverse T3 (rT3). Fetal serum T3 concentrations rise from approximately 6 ng/dL (0.09 nmol/L) at 12 weeks to 45 ng/dL (0.68 nmol/L) at term.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum TSH concentrations rise gradually from approximately 4 mU/L at 12 weeks to 8 mU/L at term.
        </p>
        <p>
        </p>
        <p>
         The fetus is dependent on maternal iodine intake, and iodine is transferred across the placenta for fetal thyroid hormone production. To meet the iodine needs of the fetus, the recommended iodine intake for a woman is higher during pregnancy (250 to 300 mcg daily) than in nonpregnant women (150 mcg daily) [
         <a href="#rid4">
          4,5
         </a>
         ]. Maternal hypothyroidism (including maternal iodine deficiency) is a risk factor for preterm birth and may have adverse effects on neurodevelopment in the offspring. (See
         <a class="medical medical_review" href="/z/d/html/7851.html" rel="external">
          "Overview of thyroid disease and pregnancy", section on 'Iodine requirements'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16609.html" rel="external">
          "Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          POSTNATAL THYROID FUNCTION
         </span>
        </p>
        <p class="headingAnchor" id="H3359914564">
         <span class="h2">
          Term infants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serum thyrotropin (thyroid-stimulating hormone [TSH]) concentrations rise abruptly to 60 to 80 mU/L within 30 to 60 minutes after delivery in healthy term babies [
         <a href="#rid6">
          6
         </a>
         ]; this rise is associated with exposure of the infant to a colder environment and clamping of the umbilical cord. The serum TSH concentration then decreases rapidly to approximately 20 mU/L 24 hours after delivery and then more slowly to 6 to 10 mU/L at one week (
         <a class="graphic graphic_figure graphicRef68673" href="/z/d/graphic/68673.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
         The initial surge in TSH stimulates thyroidal thyroxine (T4) secretion, so that serum total and free T4 concentrations rise to a peak at 24 to 36 hours of life of approximately 10 to 22 mcg/dL (129 to 283 nmol/L) and 2 to 5 ng/dL (25 to 64 pmol/L), respectively [
         <a href="#rid7">
          7
         </a>
         ]. Serum triiodothyronine (T3) concentrations also rise, to a peak of approximately 250 ng/dL (3.8 nmol/L), at the same time (
         <a class="graphic graphic_figure graphicRef68673" href="/z/d/graphic/68673.html" rel="external">
          figure 1
         </a>
         ). The increase in serum T3 is a result of increases in both thyroidal secretion and conversion of T4 to T3 in peripheral tissues.
        </p>
        <p>
         Serum T4, free T4, and T3 concentrations gradually fall in the first four weeks of life, leveling off at slightly higher values than are found in adults [
         <a href="#rid7">
          7
         </a>
         ]. At this time, the reference range for serum total T4 concentrations is 7 to 16 mcg/dL (90 to 206 nmol/L) and the reference range for serum free T4 concentrations is 0.8 to 2 ng/dL (10 to 26 pmol/L). After the first four weeks, the reference range for TSH is 0.5 to 6 mU/L, also higher than adult levels. TSH values reach the adult reference range at approximately two years of age.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Preterm infants
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Relation to gestational age
         </strong>
         – As one would expect from the above description of fetal changes during normal gestation, cord serum total and free thyroxine (T4) concentrations are proportional to either birth weight or gestational age [
         <a href="#rid8">
          8,9
         </a>
         ]. The same is true for heel stick blood values, as collected for routine newborn screening for hypothyroidism two to five days after delivery (
         <a class="graphic graphic_table graphicRef51672" href="/z/d/graphic/51672.html" rel="external">
          table 1
         </a>
         ). The cord serum T4 concentration averages 5.4 mcg/dL (70 nmol/L) in infants less than 1000 gm [
         <a href="#rid8">
          8
         </a>
         ] and 6.3 mcg/dL (81 nmol/L) in infants born at less than 30 weeks gestation [
         <a href="#rid10">
          10,11
         </a>
         ]. Cord serum free T4 concentrations are not proportionately as low, averaging 1.2 ng/dL (15 pmol/L) in infants born at less than 30 weeks gestation [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Relation to postnatal age
         </strong>
         – After birth, preterm infants undergo changes in serum thyrotropin (thyroid-stimulating hormone [TSH]), T4, and triiodothyronine (T3) concentrations that are similar to those of term infants, described above (see
         <a class="local">
          'Postnatal thyroid function'
         </a>
         above). However, these changes are quantitatively smaller, especially in the most premature infants, most likely because of immaturity of the hypothalamic-pituitary-thyroid axis [
         <a href="#rid11">
          11,12
         </a>
         ]. The reference range for thyroid hormones thus varies by gestational age and also by postnatal age (
         <a class="graphic graphic_table graphicRef72215" href="/z/d/graphic/72215.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As in term infants, serum T4 concentrations fall in the first week of life in low-birth-weight preterm infants [
         <a href="#rid8">
          8
         </a>
         ]. This fall is greater in very-low-birth-weight, more premature infants, in whom T4 clearance is more rapid. In infants from areas in which iodine deficiency is endemic, lack of adequate iodine intake contributes to the fall in serum T4 concentrations [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         After the first week, serum T4 and T3 concentrations gradually rise in the most premature infants (those born at 23 to 27 weeks gestational age). By three to six weeks of life, the values in these infants (&lt;28 weeks of gestation) overlap the range of normal in term infants, although the mean values are slightly lower (
         <a class="graphic graphic_table graphicRef72215" href="/z/d/graphic/72215.html" rel="external">
          table 2
         </a>
         ). In less premature infants judged to be healthy (30 to 35 weeks of gestation), serum T4 rises and peaks at seven days, and then falls. In these infants, the thyroid hormone measurements overlap with the reference range for a term newborn after the first week of life [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          NEWBORN SCREENING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Three major strategies are used for newborn screening:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Initial thyroxine (T4) assay, with reflex thyrotropin (thyroid-stimulating hormone [TSH]) assay
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Initial TSH assay
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Simultaneous T4 and TSH assay
        </p>
        <p>
        </p>
        <p>
         Most programs in the United States started with the initial T4/reflex TSH testing approach but many have switched to initial TSH testing, citing that this method is more cost-effective with lower false-positive rates. Infants with a delayed rise in blood TSH concentration (who typically have a low T4-normal TSH on initial testing) and those with central hypothyroidism are detected more reliably by the initial T4/follow-up TSH assay method, whereas infants with subclinical hypothyroidism (high blood TSH, normal blood T4) are detected more reliably by TSH testing. (See
         <a class="medical medical_review" href="/z/d/html/5836.html" rel="external">
          "Clinical features and detection of congenital hypothyroidism", section on 'Technique'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H339439627">
         <span class="h2">
          Implications of variation in thyroid function in preterm infants
         </span>
        </p>
        <p class="headingAnchor" id="H136005103">
         <span class="h3">
          False-positive and false-negative screening results
         </span>
         <span class="headingEndMark">
          —
         </span>
         Compared with full-term infants, preterm infants are more prone to both false-positive and false-negative results of initial newborn screening tests for hypothyroidism. This is due to physiologic differences in thyroid function, including the lower T4 levels after birth and the later rise in TSH levels with maturation of the hypothalamic-pituitary-thyroid axis, as well as fluctuations as they recover from nonthyroidal illness. A pattern of a more dramatic delayed TSH elevation occurs in some preterm infants; when these cases are included, the incidence of congenital hypothyroidism is higher in preterm than term infants. Studies report that most preterm babies with delayed TSH elevation have transient hypothyroidism. If these transient cases are excluded, the prevalence of permanent congenital primary hypothyroidism in preterm infants is likely similar to that in term infants [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         Because of the potential for false-negative and false-positive screening results in this population, we suggest that very preterm infants (eg, birth weight &lt;1500 g or gestational age &lt;32 weeks) undergo a routine repeat screening test (eg, at two to four weeks of age) (
         <a class="graphic graphic_algorithm graphicRef51189" href="/z/d/graphic/51189.html" rel="external">
          algorithm 1
         </a>
         ). This strategy applies regardless of the thyroid function test approach used by the screening program, and is recommended by many programs [
         <a href="#rid16">
          16-18
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          False-positive results
         </strong>
         – Preterm infants often have a characteristic fluctuation in thyroid hormones during the first few weeks of life, consisting of transient mild hypothyroxinemia, followed by a compensatory mild and transient elevation in serum TSH levels. These abnormalities can be considered physiologic because they usually resolve spontaneously, but can cause false-positive results of initial newborn screening tests.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The transient hypothyroxinemia (low T4) may cause false-positive results in screening programs that use T4 as the primary screening test [
         <a href="#rid19">
          19
         </a>
         ]. Preterm infants (&lt;37 weeks gestation) account for approximately 12 percent of births, yet they account for a much higher percent of infants with blood T4 concentrations below a selected cutoff, (eg, &lt;10
         <sup>
          th
         </sup>
         percentile, equivalent to approximately 8 mcg/dL [103 nmol/L]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The resultant TSH rise also may cause false-positive results, especially in infants with extremely low birth weight [
         <a href="#rid20">
          20
         </a>
         ]. The TSH elevation usually is mild (typically 6 to 15 mU/L), and usually returns to normal within the first few weeks of life. Thus, this pattern can be considered a normal response to the physiologic hypothyroxinemia seen in some healthy preterm infants.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some preterm infants have greater and more persistent deviations from normal values, typically seen as low screening blood T4 values and delayed elevation in screening TSH values (eg, TSH rising to &gt;20 mU/L [serum] or &gt;10 mU/L [whole blood] at 15 to 30 days of age) [
         <a href="#rid20">
          20-22
         </a>
         ]. In such cases, it may be difficult to distinguish between physiologic fluctuations in thyroid hormones due to prematurity and true primary hypothyroidism, which may be transient or permanent. While some infants with a TSH elevation as high as 50 mU/L may ultimately have normal thyroid function without treatment [
         <a href="#rid23">
          23
         </a>
         ], they may still be at risk for adverse effects on brain development [
         <a href="#rid24">
          24
         </a>
         ]. Until there are randomized controlled trials to address this question, we recommend treating these patients. A clinical strategy for making the diagnosis of primary hypothyroidism and initiating treatment is outlined below. (See
         <a class="local">
          'Primary hypothyroidism'
         </a>
         below and
         <a class="local">
          'Transient versus permanent hypothyroidism'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          False-negative results
         </strong>
         – In addition, some preterm infants with congenital primary hypothyroidism are more likely to have a delayed rise in serum TSH, creating the potential for a false-negative result in screening programs that employ a primary TSH test. This form of hypothyroidism developing over time would be missed if screening were performed only once within the first few days of life. For example, infants with birth weight &lt;1500 g who are ultimately shown to have primary hypothyroidism have a rate of delayed TSH elevation between 1:54 to 1:294 [
         <a href="#rid20">
          20,23,25,26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4202024881">
         <span class="h3">
          Effects of nonthyroidal illness
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thyroid function testing also may be affected by medical complications associated with preterm birth, such as respiratory distress syndrome (RDS) or intrauterine growth restriction [
         <a href="#rid27">
          27,28
         </a>
         ]. Preterm infants with RDS and other medical problems tend to not have the expected postnatal increases in serum TSH, T4, and triiodothyronine (T3) concentrations; their serum T4 and T3 concentrations may decrease at 24 hours of age and be low until the infant recovers from their acute illness or gains weight [
         <a href="#rid29">
          29,30
         </a>
         ]. Thereafter, the concentrations rise slowly in the survivors [
         <a href="#rid29">
          29
         </a>
         ]. A study of late preterm and term infants with RDS showed that serum free T4 remains low for the first five days of life; the decrease in free T4 levels correlates with severity of illness scores [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         These medical conditions tend to depress serum total T4 concentrations more often than serum free T4 concentrations [
         <a href="#rid32">
          32
         </a>
         ]. Thus, at least some of the fall in serum total T4 concentrations is a result of decreases in serum protein binding of T4. In contrast, serum total and free T3 concentrations are low, because peripheral conversion of T4 to T3 is decreased. In addition, some very sick infants have low serum TSH concentrations, which further lowers serum T4 and T3 concentrations (see
         <a class="medical medical_review" href="/z/d/html/7817.html" rel="external">
          "Thyroid function in nonthyroidal illness"
         </a>
         ). Furthermore, if sick preterm infants are treated with glucocorticoids [
         <a href="#rid33">
          33
         </a>
         ] or dopamine [
         <a href="#rid34">
          34
         </a>
         ], these drugs also may decrease TSH secretion.
        </p>
        <p class="headingAnchor" id="H3445492285">
         <span class="h3">
          Reversible/transient causes of hypothyroidism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Exposures that can cause transient hypothyroidism in neonates and young infants include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Iodine exposure, including from iodinated contrast agents
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maternal iodine deficiency, which varies globally
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maternal autoimmune thyroid disease due to placental transfer of antithyroid drugs or blocking antibodies
        </p>
        <p>
        </p>
        <p>
         The US Food and Drug Administration released a warning about the risk of iodine-induced hypothyroidism in infants receiving iodinated contrast media for medical imaging [
         <a href="#rid35">
          35
         </a>
         ]. Preterm and acutely ill term infants, typically those with congenital heart disease or renal insufficiency, appear to be at highest risk for hypothyroidism. We recommend that preterm infants receiving iodinated contrast media undergo measurement of serum TSH approximately two to three weeks after exposure. (See
         <a class="local">
          'Diagnosis and treatment decisions'
         </a>
         below.)
        </p>
        <p>
         These issues are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5836.html" rel="external">
          "Clinical features and detection of congenital hypothyroidism", section on 'Transient congenital hypothyroidism'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3530046106">
         <span class="h2">
          Screening protocol and interpretation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Newborn screening for hypothyroidism is recommended for all preterm infants, as it is for full-term infants. Blood for screening is collected onto filter paper cards after heel prick, and the cards are then sent to a centralized laboratory for testing. The initial sample is usually collected between 24 and 48 hours after birth. Most newborn screening programs obtain a routine second specimen at two to four weeks of age in preterm infants, both to resolve abnormal results on the first test (low T4 in a primary T4-reflex TSH test program) and to detect cases with delayed TSH elevation (in primary TSH test programs). The threshold birth weight or gestational age for which the additional screening test is performed varies among screening programs. For babies &lt;32 weeks gestation, many programs will obtain an additional third specimen around four to six weeks of age (or before discharge, whichever comes first) [
         <a href="#rid36">
          36
         </a>
         ]. (See
         <a class="local">
          'Implications of variation in thyroid function in preterm infants'
         </a>
         above.)
        </p>
        <p>
         The timing and type of follow-up testing depends on the initial results, as outlined below (
         <a class="graphic graphic_algorithm graphicRef51189" href="/z/d/graphic/51189.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H2230727575">
         <span class="h3">
          Initial and follow-up screening tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial screen is performed on a sample collected between 24 and 48 hours after birth. The recommended response to screening results is as follows (
         <a class="graphic graphic_algorithm graphicRef51189" href="/z/d/graphic/51189.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Normal results
         </strong>
         – Preterm infants with normal results on the initial newborn screen should have a second newborn screen performed, recommended at two to four weeks of age. If the second screen is performed before 36 weeks corrected gestational age, a repeat (third) screening test is recommended four weeks later (six to eight weeks of life) or at 36 weeks corrected gestational age, whichever is earlier [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Abnormal results
         </strong>
         – Preterm infants with elevated TSH on any of the screening tests (with low T4 or normal T4) should undergo measurement of
         <strong>
          serum
         </strong>
         free T4 and TSH. (See
         <a class="local">
          'Confirmatory serum testing'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If the abnormal result is a low T4 and non-elevated (normal or low) TSH, most programs recommend a second screening test (on a heel stick sample) performed at two to four weeks of age. This is a common finding in preterm babies when screened by the primary T4-reflex TSH method, and most infants will have normal results on the second screen (see
         <a class="local">
          'Hypothyroxinemia of prematurity: Treatment versus observation?'
         </a>
         below). Those with persistent low T4 require further evaluation with serum testing to evaluate for the possibility of central hypothyroidism, as described below.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2225874179">
         <span class="h3">
          Confirmatory serum testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Preterm infants with abnormal results on the initial screen or subsequent screening tests should undergo measurement of
         <strong>
          serum
         </strong>
         free T4 and TSH. If the serum screening is performed at two to four weeks of age and is entirely normal, then no further screening is needed.
        </p>
        <p>
         Interpretation of abnormal results is discussed in the next section.
        </p>
        <p class="headingAnchor" id="H1909271966">
         <span class="h1">
          DIAGNOSIS AND TREATMENT DECISIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The possibility of congenital hypothyroidism is suspected based on abnormal results of the first or subsequent newborn screens. The diagnosis is confirmed by serum testing.
        </p>
        <p class="headingAnchor" id="H3100132955">
         <span class="h2">
          Threshold for abnormal TSH
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most cases, serum thyrotropin (thyroid-stimulating hormone [TSH]) is the key diagnostic test. The threshold for defining an elevated TSH level varies only slightly by gestational age; once a preterm infant reaches a postnatal "term" age, ranges for term infants can be used. In general, a serum TSH &gt;10 mU/L is elevated for preterm babies who have not reached a "term" postnatal age (&lt;37 weeks), while a TSH &gt;6 mU/L is the cutoff for babies who have reached "term" postnatal age (≥37 weeks).
        </p>
        <p>
         Free thyroxine (T4) and T4 levels vary with gestational and postnatal age. The thyroid function data in the table (
         <a class="graphic graphic_table graphicRef72215" href="/z/d/graphic/72215.html" rel="external">
          table 2
         </a>
         ) can be used as a guideline in interpreting serum thyroid function test results, based on gestational age and postnatal age of the baby (where normal is defined as ±2 standard deviations).
        </p>
        <p>
         The results of confirmatory serum testing are interpreted as follows:
        </p>
        <p class="headingAnchor" id="H397784994">
         <span class="h2">
          Primary hypothyroidism
         </span>
         <span class="headingEndMark">
          —
         </span>
         The finding of
         <strong>
          low free T4 and elevated TSH
         </strong>
         on serum testing is diagnostic of primary hypothyroidism (
         <a class="graphic graphic_algorithm graphicRef51189" href="/z/d/graphic/51189.html" rel="external">
          algorithm 1
         </a>
         ). These infants should be treated using a starting
         <a class="drug drug_pediatric" data-topicid="12550" href="/z/d/drug information/12550.html" rel="external">
          levothyroxine
         </a>
         dose of 10 to 15 mcg/kg/day. (See
         <a class="medical medical_review" href="/z/d/html/5837.html" rel="external">
          "Treatment and prognosis of congenital hypothyroidism"
         </a>
         .)
        </p>
        <p>
         In some cases, the hypothyroidism will prove to be transient and
         <a class="drug drug_pediatric" data-topicid="12550" href="/z/d/drug information/12550.html" rel="external">
          levothyroxine
         </a>
         can be withdrawn later. (See
         <a class="local">
          'Transient versus permanent hypothyroidism'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3817817321">
         <span class="h2">
          Central hypothyroidism
         </span>
         <span class="headingEndMark">
          —
         </span>
         The finding of
         <strong>
          low free
         </strong>
         <strong>
          T4 and non-elevated (normal or low) TSH
         </strong>
         raises the possibility of central hypothyroidism (
         <a class="graphic graphic_algorithm graphicRef51189" href="/z/d/graphic/51189.html" rel="external">
          algorithm 1
         </a>
         ). If the initial free T4 test was performed by the standard "analog" assay, it should be repeated by measuring free T4 by equilibrium dialysis, a more accurate type of assay that can aid in distinguishing nonthyroidal illness syndrome from central hypothyroidism [
         <a href="#rid38">
          38,39
         </a>
         ]. Some preterm infants may manifest low serum free T4 levels on both the standard analog and equilibrium dialysis method. In these cases, it may be impossible to separate these results, more likely attributable to prematurity and nonthyroidal illness syndrome, from the relatively rare case of central hypothyroidism. Evidence for other pituitary hormone deficiencies or congenital midline brain defects (see below) strengthens the possibility of true central hypothyroidism.
        </p>
        <p>
         We recommend
         <a class="drug drug_pediatric" data-topicid="12550" href="/z/d/drug information/12550.html" rel="external">
          levothyroxine
         </a>
         treatment in those cases where the free T4 measured by equilibrium dialysis is low after four weeks of age.
        </p>
        <p>
         Central hypothyroidism can be due to isolated TSH deficiency, but is more likely in infants with evidence for other pituitary hormone deficiencies, presence on imaging of pituitary abnormalities (eg, ectopic posterior pituitary gland) or midline defects (eg, absent septum pellucidum), or a history of central nervous system insult that may have caused hypothalamic-pituitary injury. Therefore, all cases with laboratory testing compatible with central hypothyroidism should be evaluated for other pituitary hormone deficiencies, especially central adrenal insufficiency, if not already done. (See
         <a class="medical medical_review" href="/z/d/html/5836.html" rel="external">
          "Clinical features and detection of congenital hypothyroidism", section on 'Central hypothyroidism'
         </a>
         .)
        </p>
        <p>
         Thyrotropin-releasing hormone (TRH) stimulation testing may also be used to support the diagnosis of central hypothyroidism. Infants with central hypothyroidism tend to have a delayed but excessive TSH increase after TRH stimulation, followed by delayed TSH decrease [
         <a href="#rid40">
          40
         </a>
         ]. TRH is available in some countries in Europe but not in the United States.
        </p>
        <p class="headingAnchor" id="H2834089563">
         <span class="h2">
          Subclinical hypothyroidism
         </span>
         <span class="headingEndMark">
          —
         </span>
         The interpretation of
         <strong>
          normal free T4 with slightly elevated TSH
         </strong>
         depends on the age of the infant:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Before two weeks of age, these results usually reflect transient TSH elevations following recovery from a "physiologically" low T4 level due to prematurity. These infants should not be treated, but serum testing should be repeated at two to four weeks of age. In most cases, the TSH will normalize. (See
         <a class="local">
          'Implications of variation in thyroid function in preterm infants'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         After four to six weeks of age, persistently elevated TSH with normal free T4 likely represents subclinical hypothyroidism. In some infants with mildly abnormal thyroid function tests, eg, infants with serum TSH 6 to 20 mU/L and normal free T4 results, information from imaging studies (typically, thyroid ultrasound examination) will help in the decision to start
         <a class="drug drug_pediatric" data-topicid="12550" href="/z/d/drug information/12550.html" rel="external">
          levothyroxine
         </a>
         (eg, finding thyroid hypoplasia or an ectopic gland) or to further monitor (eg, a eutopic, normal-appearing gland). If the decision is made to treat these infants with subclinical hypothyroidism, we recommend starting levothyroxine at a lower dose (8 to 10 mcg/kg/day) than used to treat overt congenital primary hypothyroidism. Thyroid function should be reevaluated after two to three years of age; clinical judgment is required in managing these cases. (See
         <a class="medical medical_review" href="/z/d/html/5837.html" rel="external">
          "Treatment and prognosis of congenital hypothyroidism", section on 'Assessment of permanent versus transient hypothyroidism'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3392985574">
         <span class="h2">
          Thyroxine-binding globulin deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thyroxine-binding globulin (TBG) deficiency, detected by screening programs that use a primary T4 methodology, is characterized by low serum total T4 but normal free T4 and TSH. The diagnosis is confirmed by measuring TBG concentrations, which are low for age. These infants have normal thyroid function and do not require treatment.
        </p>
        <p class="headingAnchor" id="H3762236060">
         <span class="h1">
          TRANSIENT VERSUS PERMANENT HYPOTHYROIDISM
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infants with hypothyroidism diagnosed on serum testing as outlined above should be treated with
         <a class="drug drug_pediatric" data-topicid="12550" href="/z/d/drug information/12550.html" rel="external">
          levothyroxine
         </a>
         . However, in some of these infants, the hypothyroidism will be transient and resolve spontaneously within months to years. As an example, in one study, 24 preterm infants were diagnosed with hypothyroidism by serum testing at 15 to 30 days of age (thyrotropin [thyroid-stimulating hormone (TSH)] &gt;10 m/L) and were treated with levothyroxine [
         <a href="#rid41">
          41
         </a>
         ]. When thyroid function was retested at two years of age after discontinuation of levothyroxine therapy, 75 percent had normal thyroid function, while the remainder had permanent hypothyroidism.
        </p>
        <p>
         Because no clinical or laboratory characteristics reliably predict outcome, we recommend treating these children until two years of age; at that time, thyroid hormone can be discontinued and thyroid function checked one month later. (See
         <a class="medical medical_review" href="/z/d/html/5837.html" rel="external">
          "Treatment and prognosis of congenital hypothyroidism", section on 'Assessment of permanent versus transient hypothyroidism'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4127097768">
         <span class="h1">
          HYPOTHYROXINEMIA OF PREMATURITY: TREATMENT VERSUS OBSERVATION?
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thyroid hormone replacement (not recommended)
         </strong>
         – There is insufficient evidence to support routine thyroid hormone replacement (
         <a class="drug drug_pediatric" data-topicid="12550" href="/z/d/drug information/12550.html" rel="external">
          levothyroxine
         </a>
         ) for preterm infants, unless they have confirmed primary or central hypothyroidism, as defined above (see
         <a class="local">
          'Diagnosis and treatment decisions'
         </a>
         above). Available evidence has not demonstrated benefit in this population, although larger trials with long-term follow-up are needed to definitively answer this question. Instead, interventions should focus on avoiding the established risk factors for transient hypothyroxinemia, which are iodine deficiency, exposure to excess iodine, nonthyroidal illness, and use of medications that affect the hypothalamic-pituitary-thyroid axis [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The relevant evidence is outlined below:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Association with comorbidities
         </strong>
         – Some investigators have proposed that the hypothyroxinemia of prematurity is a state of clinical hypothyroidism and that all premature infants might benefit from thyroid hormone replacement (or iodide treatment if deficient) until the hypothalamic-pituitary-thyroid axis matures. This hypothesis arises from observations of low thyroid hormone levels in preterm infants, in combination with nonspecific symptoms and signs that might be attributed to hypothyroidism, such as hypothermia, jaundice, immature pulmonary function (with low surfactant concentrations), apnea, bradycardia, slow oral feeding, sluggish gut motility and constipation, edema, lethargy, hypotonia, and slow growth and development [
         <a href="#rid43">
          43
         </a>
         ]. However, available evidence has
         <strong>
          not
         </strong>
         demonstrated benefits of routine thyroid hormone replacement or iodide treatment for these infants, as discussed below.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Association with neurodevelopmental outcomes
         </strong>
         – Several observational studies demonstrate a relationship between the low T4 concentrations in premature infants and intellectual disability or problems in neurodevelopment [
         <a href="#rid44">
          44-49
         </a>
         ]. While some report an increased odds ratio for lower intelligence quotient (IQ) and disabling cerebral palsy [
         <a href="#rid45">
          45
         </a>
         ], below-normal attention span [
         <a href="#rid47">
          47
         </a>
         ], and vision disturbances [
         <a href="#rid48">
          48
         </a>
         ], others did not find an association with developmental quotient at one year [
         <a href="#rid44">
          44
         </a>
         ] or neurodevelopmental outcome at 19 years [
         <a href="#rid49">
          49
         </a>
         ]. Because it is difficult to adjust for other complications of prematurity that may have contributed to the outcome, a causal relationship has not been established.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The efficacy of routine thyroid hormone replacement in preterm infants has been investigated in several studies, with endpoints including growth, recovery from respiratory distress syndrome, neurologic development, and mortality; most have not demonstrated a benefit [
         <a href="#rid50">
          50-56
         </a>
         ]. A randomized clinical trial comparing placebo versus
         <a class="drug drug_pediatric" data-topicid="12550" href="/z/d/drug information/12550.html" rel="external">
          levothyroxine
         </a>
         treatment in 200 infants &lt;30 weeks gestational age did not show benefit [
         <a href="#rid57">
          57
         </a>
         ], although subsequent analysis in the subgroup &lt;27 weeks gestation appeared to show benefit in one score of neurodevelopment [
         <a href="#rid58">
          58
         </a>
         ]. However, in follow-up studies at 5.7 years of age [
         <a href="#rid59">
          59
         </a>
         ] and again at 10 years of age, this benefit was no longer present [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         This issue continues to be unresolved. In a study of preterm infants weighing &lt;1500 g, a comparison of outcomes in infants with and without hypothyroxinemia did not find any significant differences in neurodevelopmental, visual, or hearing impairment at five years of age [
         <a href="#rid61">
          61
         </a>
         ]. A double-blind, randomized, placebo-controlled trial in preterm babies &lt;28 weeks gestation showed statistically better motor, language, and cognitive domains in the group treated with
         <a class="drug drug_pediatric" data-topicid="12550" href="/z/d/drug information/12550.html" rel="external">
          levothyroxine
         </a>
         [
         <a href="#rid62">
          62
         </a>
         ]. However, the investigators concluded that the improvements shown were not strong enough to warrant a change in practice.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Larger randomized trials with long-term follow-up are needed to definitively determine whether routine thyroid hormone replacement is beneficial in preterm infants [
         <a href="#rid63">
          63
         </a>
         ]. This is especially important because of the large size of this population (approximately 25,000 infants born at &lt;28 weeks' gestation each year in the United States alone) and because this population is already at risk for cognitive disabilities.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supplemental
         </strong>
         <strong>
          iodine
         </strong>
         <strong>
          (not recommended)
         </strong>
         – Given that preterm infants are at risk for iodine deficiency, a randomized controlled trial of sodium iodide 30 mcg/kg/day versus placebo, given until the equivalent of 34 weeks gestation, was undertaken in 1273 preterm infants in the United Kingdom [
         <a href="#rid64">
          64
         </a>
         ]. Follow-up Bayley Scales of Infant Development III did not show any significant differences in language, motor, or overall cognitive scores at two years of age. As with all infants, preterm infants should receive the recommended dietary allowance of iodine (30 mcg/kg/day).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2698493815">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/141293.html" rel="external">
          "Society guideline links: Pediatric thyroid disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postnatal changes in thyroid hormones
         </strong>
         – In full-term babies, levels of thyrotropin (thyroid-stimulating hormone [TSH]), thyroxine (T4), and triiodothyronine (T3) rise sharply after birth, fall rapidly during the first five days of life, and then fall more gradually between one and four weeks of life (
         <a class="graphic graphic_figure graphicRef68673" href="/z/d/graphic/68673.html" rel="external">
          figure 1
         </a>
         ). Preterm infants undergo similar but smaller changes in thyroid hormone levels. The reference ranges for thyroid hormones thus vary by birth weight (
         <a class="graphic graphic_table graphicRef51672" href="/z/d/graphic/51672.html" rel="external">
          table 1
         </a>
         ) and also by gestational age and postnatal age (
         <a class="graphic graphic_table graphicRef72215" href="/z/d/graphic/72215.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Postnatal thyroid function'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Newborn screening
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          All preterm infants
         </strong>
         – As for all newborns, preterm infants should undergo routine screening for hypothyroidism (
         <a class="graphic graphic_algorithm graphicRef51189" href="/z/d/graphic/51189.html" rel="external">
          algorithm 1
         </a>
         ). The first screening specimen is most commonly obtained between 24 and 48 hours after birth. (See
         <a class="local">
          'Screening protocol and interpretation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Very preterm infants
         </strong>
         – We recommend an additional screening test in very preterm infants (eg, birth weight &lt;1500 g or gestational age &lt;32 weeks) (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ) (
         <a class="graphic graphic_algorithm graphicRef51189" href="/z/d/graphic/51189.html" rel="external">
          algorithm 1
         </a>
         ). The second test is recommended at two to four weeks of age. In many programs, three screening tests are performed in infants who remain hospitalized beyond one month of age (at 24 to 48 hours, 10 to 14 days, and four to six weeks of age). (See
         <a class="local">
          'Initial and follow-up screening tests'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         This additional screening test reduces the risk of misleading screening results, which are common in premature infants because of delayed rise in serum TSH (causing false-negative results) or physiologic immaturity (causing false-positive results). (See
         <a class="local">
          'False-positive and false-negative screening results'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Confirmatory testing and treatment
         </strong>
         <strong>
          decisions
         </strong>
         – Abnormal results of screening tests should be confirmed by serum studies consisting of TSH and free T4 (or T4 and some measure of thyroid hormone-binding proteins) (
         <a class="graphic graphic_algorithm graphicRef51189" href="/z/d/graphic/51189.html" rel="external">
          algorithm 1
         </a>
         ). The results should be interpreted based on the reference range for gestational age and postnatal age (
         <a class="graphic graphic_table graphicRef72215" href="/z/d/graphic/72215.html" rel="external">
          table 2
         </a>
         ). The cutoff for defining an elevated TSH level varies slightly by gestational age; in general, a serum TSH &gt;10 mU/L is elevated for preterm babies who have not reached "term" postnatal age, while a TSH &gt;6 mU/L is the cutoff for babies who have reached "term" postnatal age. (See
         <a class="local">
          'Diagnosis and treatment decisions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Low free T4, elevated TSH
         </strong>
         – Preterm infants with this result on screening and confirmatory serum tests have primary hypothyroidism and should be treated with
         <a class="drug drug_pediatric" data-topicid="12550" href="/z/d/drug information/12550.html" rel="external">
          levothyroxine
         </a>
         . (See
         <a class="local">
          'Primary hypothyroidism'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5837.html" rel="external">
          "Treatment and prognosis of congenital hypothyroidism"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Normal free T4, mildly elevated TSH
         </strong>
         – This finding may be transient and does not require immediate treatment. If it persists after four weeks of age, the infant may have "subclinical hypothyroidism"; we recommend
         <a class="drug drug_pediatric" data-topicid="12550" href="/z/d/drug information/12550.html" rel="external">
          levothyroxine
         </a>
         treatment in these cases. (See
         <a class="local">
          'Subclinical hypothyroidism'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Low free T4, normal TSH
         </strong>
         – If this result is found on initial confirmatory serum testing, diagnostic possibilities are central hypothyroidism (uncommon) or nonthyroidal illness syndrome. Repeat serum studies should be performed, with repeat free T4 measurement by equilibrium dialysis. Evidence for other pituitary hormone deficiencies or congenital midline brain defects strengthens the possibility of true central hypothyroidism. We recommend
         <a class="drug drug_pediatric" data-topicid="12550" href="/z/d/drug information/12550.html" rel="external">
          levothyroxine
         </a>
         treatment in cases with a subnormal free T4 confirmed by equilibrium dialysis method. (See
         <a class="local">
          'Central hypothyroidism'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Low total T4 with normal free T4
         </strong>
         – This result (with normal TSH) is likely caused by low serum thyroid hormone-binding globulin (TBG) and does not require treatment. (See
         <a class="local">
          'Thyroxine-binding globulin deficiency'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infants with nonthyroidal illness
         </strong>
         – In infants with clinical features of nonthyroidal illness (eg, respiratory distress syndrome) and characteristic abnormalities in thyroid hormones (normal or low serum total and free T4 concentrations, low serum T3 concentrations, and low-normal or low serum TSH concentrations), beneficial effects of
         <a class="drug drug_pediatric" data-topicid="12550" href="/z/d/drug information/12550.html" rel="external">
          levothyroxine
         </a>
         treatment have not been established. (See
         <a class="local">
          'Effects of nonthyroidal illness'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypothyroxinemia of prematurity
         </strong>
         – Abnormal thyroid function tests on the initial newborn screen in premature infants often normalize by the second or third newborn screens. There is insufficient evidence to support routine thyroid hormone replacement (
         <a class="drug drug_pediatric" data-topicid="12550" href="/z/d/drug information/12550.html" rel="external">
          levothyroxine
         </a>
         ) in preterm infants unless they have confirmed primary or central hypothyroidism. (See
         <a class="local">
          'Hypothyroxinemia of prematurity: Treatment versus observation?'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Thorpe-Beeston JG, Nicolaides KH, Felton CV, et al. Maturation of the secretion of thyroid hormone and thyroid-stimulating hormone in the fetus. N Engl J Med 1991; 324:532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thorpe-Beeston JG, Nicolaides KH, McGregor AM. Fetal thyroid function. Thyroid 1992; 2:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Obregon MJ, Calvo RM, Del Rey FE, de Escobar GM. Ontogenesis of thyroid function and interactions with maternal function. Endocr Dev 2007; 10:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid 2017; 27:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delange F. Iodine requirements during pregnancy, lactation and the neonatal period and indicators of optimal iodine nutrition. Public Health Nutr 2007; 10:1571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher DA, Odell WD. Acute release of thyrotropin in the newborn. J Clin Invest 1969; 48:1670.
          </a>
         </li>
         <li class="breakAll">
          Fisher DA, Brown RS. Thyroid physiology in the perinatal period and during childhood. In: Werner's and Ingbar's The Thyroid, Braverman LE, Utiger RD (Eds), Lippincott Williams and Wilkins, Philadelphia 2000. p.959.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams FL, Simpson J, Delahunty C, et al. Developmental trends in cord and postpartum serum thyroid hormones in preterm infants. J Clin Endocrinol Metab 2004; 89:5314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams FL, Mires GJ, Barnett C, et al. Transient hypothyroxinemia in preterm infants: the role of cord sera thyroid hormone levels adjusted for prenatal and intrapartum factors. J Clin Endocrinol Metab 2005; 90:4599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein AH, Oddie TH, Parslow M, et al. Developmental changes in pituitary-thyroid function in the human fetus and newborn. Early Hum Dev 1982; 6:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adams LM, Emery JR, Clark SJ, et al. Reference ranges for newer thyroid function tests in premature infants. J Pediatr 1995; 126:122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy N, Hume R, van Toor H, et al. The hypothalamic-pituitary-thyroid axis in preterm infants; changes in the first 24 hours of postnatal life. J Clin Endocrinol Metab 2004; 89:2824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ares S, Escobar-Morreale HF, Quero J, et al. Neonatal hypothyroxinemia: effects of iodine intake and premature birth. J Clin Endocrinol Metab 1997; 82:1704.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carrascosa A, Ruiz-Cuevas P, Potau N, et al. Thyroid function in seventy-five healthy preterm infants thirty to thirty-five weeks of gestational age: a prospective and longitudinal study during the first year of life. Thyroid 2004; 14:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Srinivasan R, Harigopal S, Turner S, Cheetham T. Permanent and transient congenital hypothyroidism in preterm infants. Acta Paediatr 2012; 101:e179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frank JE, Faix JE, Hermos RJ, et al. Thyroid function in very low birth weight infants: effects on neonatal hypothyroidism screening. J Pediatr 1996; 128:548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Léger J, Olivieri A, Donaldson M, et al. European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism. J Clin Endocrinol Metab 2014; 99:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LaFranchi SH. Screening preterm infants for congenital hypothyroidism: better the second time around. J Pediatr 2014; 164:1259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uhrmann S, Marks KH, Maisels MJ, et al. Frequency of transient hypothyroxinaemia in low birthweight infants. Potential pitfall for neonatal screening programmes. Arch Dis Child 1981; 56:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mandel SJ, Hermos RJ, Larson CA, et al. Atypical hypothyroidism and the very low birthweight infant. Thyroid 2000; 10:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell ML, Walraven C, Rojas DA, et al. Screening very-low-birthweight infants for congenital hypothyroidism. Lancet 1994; 343:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hunter MK, Mandel SH, Sesser DE, et al. Follow-up of newborns with low thyroxine and nonelevated thyroid-stimulating hormone-screening concentrations: results of the 20-year experience in the Northwest Regional Newborn Screening Program. J Pediatr 1998; 132:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woo HC, Lizarda A, Tucker R, et al. Congenital hypothyroidism with a delayed thyroid-stimulating hormone elevation in very premature infants: incidence and growth and developmental outcomes. J Pediatr 2011; 158:538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zung A, Radi A, Almashanu S. The natural history of congenital hypothyroidism with delayed TSH elevation in neonatal intensive care newborns. Clin Endocrinol (Oxf) 2020; 92:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bijarnia S, Wilcken B, Wiley VC. Newborn screening for congenital hypothyroidism in very-low-birth-weight babies: the need for a second test. J Inherit Metab Dis 2011; 34:827.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaluarachchi DC, Allen DB, Eickhoff JC, et al. Increased Congenital Hypothyroidism Detection in Preterm Infants with Serial Newborn Screening. J Pediatr 2019; 207:220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisher DA. Euthyroid low thyroxine (T4) and triiodothyronine (T3) states in prematures and sick neonates. Pediatr Clin North Am 1990; 37:1297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fily A, Pierrat V, Delporte V, et al. Factors associated with neurodevelopmental outcome at 2 years after very preterm birth: the population-based Nord-Pas-de-Calais EPIPAGE cohort. Pediatrics 2006; 117:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uhrmann S, Marks KH, Maisels MJ, et al. Thyroid function in the preterm infant: a longitudinal assessment. J Pediatr 1978; 92:968.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simpson J, Williams FL, Delahunty C, et al. Serum thyroid hormones in preterm infants and relationships to indices of severity of intercurrent illness. J Clin Endocrinol Metab 2005; 90:1271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paul DA, Mackley A, Yencha EM. Thyroid function in term and late preterm infants with respiratory distress in relation to severity of illness. Thyroid 2010; 20:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Job L, Emery JR, Hopper AO, et al. Serum free thyroxine concentration is not reduced in premature infants with respiratory distress syndrome. J Pediatr 1997; 131:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arai H, Goto R, Matsuda T, Takahashi T. Relationship between free T4 levels and postnatal steroid therapy in preterm infants. Pediatr Int 2009; 51:800.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carrascosa A, Ruiz-Cuevas P, Clemente M, et al. Thyroid function in 76 sick preterm infants 30-36 weeks: results from a longitudinal study. J Pediatr Endocrinol Metab 2008; 21:237.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. OPTIRAY (ioversol) injection prescribing information. 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/019710s065,020923s028lbl.pdf (Accessed on February 23, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaluarachchi DC, Allen DB, Eickhoff JC, et al. Thyroid-Stimulating Hormone Reference Ranges for Preterm Infants. Pediatrics 2019; 144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rose SR, Wassner AJ, Wintergerst KA, et al. Congenital Hypothyroidism: Screening and Management. Pediatrics 2023; 151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deming DD, Rabin CW, Hopper AO, et al. Direct equilibrium dialysis compared with two non-dialysis free T4 methods in premature infants. J Pediatr 2007; 151:404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niwa F, Kawai M, Kanazawa H, et al. Hyperthyrotropinemia at 2 weeks of age indicates thyroid dysfunction and predicts the occurrence of delayed elevation of thyrotropin in very low birth weight infants. Clin Endocrinol (Oxf) 2012; 77:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Tijn DA, de Vijlder JJ, Vulsma T. Role of the thyrotropin-releasing hormone stimulation test in diagnosis of congenital central hypothyroidism in infants. J Clin Endocrinol Metab 2008; 93:410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vigone MC, Caiulo S, Di Frenna M, et al. Evolution of thyroid function in preterm infants detected by screening for congenital hypothyroidism. J Pediatr 2014; 164:1296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams F, Hume R. The measurement, definition, aetiology and clinical consequences of neonatal transient hypothyroxinaemia. Ann Clin Biochem 2011; 48:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mercado M, Szymonowicz W, Yu VY, Gold H. Symptomatic hypothyroxinemia with normal TSH levels in preterm infants. Clin Pediatr (Phila) 1987; 26:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hadeed AJ, Asay LD, Klein AH, Fisher DA. Significance of transient postnatal hypothyroxinemia in premature infants with and without respiratory distress syndrome. Pediatrics 1981; 68:494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Den Ouden AL, Kok JH, Verkerk PH, et al. The relation between neonatal thyroxine levels and neurodevelopmental outcome at age 5 and 9 years in a national cohort of very preterm and/or very low birth weight infants. Pediatr Res 1996; 39:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reuss ML, Paneth N, Pinto-Martin JA, et al. The relation of transient hypothyroxinemia in preterm infants to neurologic development at two years of age. N Engl J Med 1996; 334:821.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simic N, Asztalos EV, Rovet J. Impact of neonatal thyroid hormone insufficiency and medical morbidity on infant neurodevelopment and attention following preterm birth. Thyroid 2009; 19:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simic N, Westall C, Astzalos EV, Rovet J. Visual abilities at 6 months in preterm infants: impact of thyroid hormone deficiency and neonatal medical morbidity. Thyroid 2010; 20:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hollanders JJ, Israëls J, van der Pal SM, et al. No Association Between Transient Hypothyroxinemia of Prematurity and Neurodevelopmental Outcome in Young Adulthood. J Clin Endocrinol Metab 2015; 100:4648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams FL, Visser TJ, Hume R. Transient hypothyroxinaemia in preterm infants. Early Hum Dev 2006; 82:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osborn DA, Hunt RW. Prophylactic postnatal thyroid hormones for prevention of morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2007; :CD005948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chowdhry P, Scanlon JW, Auerbach R, Abbassi V. Results of controlled double-blind study of thyroid replacement in very low-birth-weight premature infants with hypothyroxinemia. Pediatrics 1984; 73:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng SM, Turner MA, Gamble C, et al. An explanatory randomised placebo controlled trial of levothyroxine supplementation for babies born &lt;28 weeks' gestation: results of the TIPIT trial. Trials 2013; 14:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amato M, Guggisberg C, Schneider H. Postnatal triiodothyronine replacement and respiratory distress syndrome of the preterm infant. Horm Res 1989; 32:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valerio PG, van Wassenaer AG, de Vijlder JJ, Kok JH. A randomized, masked study of triiodothyronine plus thyroxine administration in preterm infants less than 28 weeks of gestational age: hormonal and clinical effects. Pediatr Res 2004; 55:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Wassenaer-Leemhuis A, Ares S, Golombek S, et al. Thyroid hormone supplementation in preterm infants born before 28 weeks gestational age and neurodevelopmental outcome at age 36 months. Thyroid 2014; 24:1162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Wassenaer AG, Kok JH, de Vijlder JJ, et al. Effects of thyroxine supplementation on neurologic development in infants born at less than 30 weeks' gestation. N Engl J Med 1997; 336:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Wassenaer AG, Kok JH, Briët JM, et al. Thyroid function in preterm newborns; is T4 treatment required in infants &lt; 27 weeks' gestational age? Exp Clin Endocrinol Diabetes 1997; 105 Suppl 4:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Briët JM, van Wassenaer AG, Dekker FW, et al. Neonatal thyroxine supplementation in very preterm children: developmental outcome evaluated at early school age. Pediatrics 2001; 107:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Wassenaer AG, Westera J, Houtzager BA, Kok JH. Ten-year follow-up of children born at &lt;30 weeks' gestational age supplemented with thyroxine in the neonatal period in a randomized, controlled trial. Pediatrics 2005; 116:e613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan LO, Tan MG, Poon WB. Lack of association between hypothyroxinemia of prematurity and transient thyroid abnormalities with adverse long term neurodevelopmental outcome in very low birth weight infants. PLoS One 2019; 14:e0222018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng SM, Turner MA, Weindling AM. Neurodevelopmental Outcomes at 42 Months After Thyroxine Supplementation in Infants Below 28 Weeks' Gestation: A Randomized Controlled Trial. Thyroid 2020; 30:948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           La Gamma EF, Paneth N. Clinical importance of hypothyroxinemia in the preterm infant and a discussion of treatment concerns. Curr Opin Pediatr 2012; 24:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams FLR, Ogston S, Hume R, et al. Supplemental Iodide for Preterm Infants and Developmental Outcomes at 2 Years: An RCT. Pediatrics 2017; 139.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5840 Version 31.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1899469" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Maturation of the secretion of thyroid hormone and thyroid-stimulating hormone in the fetus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1422233" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Fetal thyroid function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17684391" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Ontogenesis of thyroid function and interactions with maternal function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28056690" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18053281" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Iodine requirements during pregnancy, lactation and the neonatal period and indicators of optimal iodine nutrition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5822577" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Acute release of thyrotropin in the newborn.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5822577" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Acute release of thyrotropin in the newborn.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15531476" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Developmental trends in cord and postpartum serum thyroid hormones in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15886240" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Transient hypothyroxinemia in preterm infants: the role of cord sera thyroid hormone levels adjusted for prenatal and intrapartum factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6813103" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Developmental changes in pituitary-thyroid function in the human fetus and newborn.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7815201" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Reference ranges for newer thyroid function tests in premature infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15181064" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The hypothalamic-pituitary-thyroid axis in preterm infants; changes in the first 24 hours of postnatal life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9177368" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Neonatal hypothyroxinemia: effects of iodine intake and premature birth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15242570" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Thyroid function in seventy-five healthy preterm infants thirty to thirty-five weeks of gestational age: a prospective and longitudinal study during the first year of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22107264" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Permanent and transient congenital hypothyroidism in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8618191" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Thyroid function in very low birth weight infants: effects on neonatal hypothyroidism screening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24446653" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24657124" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Screening preterm infants for congenital hypothyroidism: better the second time around.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7212760" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Frequency of transient hypothyroxinaemia in low birthweight infants. Potential pitfall for neonatal screening programmes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11014314" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Atypical hypothyroidism and the very low birthweight infant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7905079" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Screening very-low-birthweight infants for congenital hypothyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9470003" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Follow-up of newborns with low thyroxine and nonelevated thyroid-stimulating hormone-screening concentrations: results of the 20-year experience in the Northwest Regional Newborn Screening Program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21232766" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Congenital hypothyroidism with a delayed thyroid-stimulating hormone elevation in very premature infants: incidence and growth and developmental outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32043280" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The natural history of congenital hypothyroidism with delayed TSH elevation in neonatal intensive care newborns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21331666" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Newborn screening for congenital hypothyroidism in very-low-birth-weight babies: the need for a second test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30579585" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Increased Congenital Hypothyroidism Detection in Preterm Infants with Serial Newborn Screening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2259541" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Euthyroid low thyroxine (T4) and triiodothyronine (T3) states in prematures and sick neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16452354" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Factors associated with neurodevelopmental outcome at 2 years after very preterm birth: the population-based Nord-Pas-de-Calais EPIPAGE cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/660370" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Thyroid function in the preterm infant: a longitudinal assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15613404" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Serum thyroid hormones in preterm infants and relationships to indices of severity of intercurrent illness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20151826" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Thyroid function in term and late preterm infants with respiratory distress in relation to severity of illness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9329438" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Serum free thyroxine concentration is not reduced in premature infants with respiratory distress syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19419509" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Relationship between free T4 levels and postnatal steroid therapy in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18540250" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Thyroid function in 76 sick preterm infants 30-36 weeks: results from a longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18540250" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Thyroid function in 76 sick preterm infants 30-36 weeks: results from a longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31311840" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Thyroid-Stimulating Hormone Reference Ranges for Preterm Infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36827523" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Congenital Hypothyroidism: Screening and Management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17889078" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Direct equilibrium dialysis compared with two non-dialysis free T4 methods in premature infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22168665" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Hyperthyrotropinemia at 2 weeks of age indicates thyroid dysfunction and predicts the occurrence of delayed elevation of thyrotropin in very low birth weight infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18000095" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Role of the thyrotropin-releasing hormone stimulation test in diagnosis of congenital central hypothyroidism in infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24518164" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Evolution of thyroid function in preterm infants detected by screening for congenital hypothyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20930033" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : The measurement, definition, aetiology and clinical consequences of neonatal transient hypothyroxinaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2885121" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Symptomatic hypothyroxinemia with normal TSH levels in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6798539" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Significance of transient postnatal hypothyroxinemia in premature infants with and without respiratory distress syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8825399" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The relation between neonatal thyroxine levels and neurodevelopmental outcome at age 5 and 9 years in a national cohort of very preterm and/or very low birth weight infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8596548" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The relation of transient hypothyroxinemia in preterm infants to neurologic development at two years of age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19355829" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Impact of neonatal thyroid hormone insufficiency and medical morbidity on infant neurodevelopment and attention following preterm birth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20144040" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Visual abilities at 6 months in preterm infants: impact of thyroid hormone deficiency and neonatal medical morbidity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26480285" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : No Association Between Transient Hypothyroxinemia of Prematurity and Neurodevelopmental Outcome in Young Adulthood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17079099" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Transient hypothyroxinaemia in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17253571" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Prophylactic postnatal thyroid hormones for prevention of morbidity and mortality in preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6366725" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Results of controlled double-blind study of thyroid replacement in very low-birth-weight premature infants with hypothyroxinemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23841945" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : An explanatory randomised placebo controlled trial of levothyroxine supplementation for babies born&lt;28 weeks' gestation: results of the TIPIT trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2634614" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Postnatal triiodothyronine replacement and respiratory distress syndrome of the preterm infant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14630985" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : A randomized, masked study of triiodothyronine plus thyroxine administration in preterm infants less than 28 weeks of gestational age: hormonal and clinical effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24684245" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Thyroid hormone supplementation in preterm infants born before 28 weeks gestational age and neurodevelopmental outcome at age 36 months.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8970936" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Effects of thyroxine supplementation on neurologic development in infants born at less than 30 weeks' gestation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9439908" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Thyroid function in preterm newborns; is T4 treatment required in infants&lt;27 weeks' gestational age?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11335749" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Neonatal thyroxine supplementation in very preterm children: developmental outcome evaluated at early school age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16234230" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Ten-year follow-up of children born at&lt;30 weeks' gestational age supplemented with thyroxine in the neonatal period in a randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31513612" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Lack of association between hypothyroxinemia of prematurity and transient thyroid abnormalities with adverse long term neurodevelopmental outcome in very low birth weight infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32070246" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Neurodevelopmental Outcomes at 42 Months After Thyroxine Supplementation in Infants Below 28 Weeks' Gestation: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22273635" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Clinical importance of hypothyroxinemia in the preterm infant and a discussion of treatment concerns.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28557747" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Supplemental Iodide for Preterm Infants and Developmental Outcomes at 2 Years: An RCT.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
